{
    "root": "c2e18240-ed8e-4b5d-9fb4-3ce104d87a38",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "VIGAFYDE",
    "value": "20250227",
    "ingredients": [
        {
            "name": "VIGABATRIN",
            "code": "GR120KRT6K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63638"
        }
    ],
    "indications": {
        "text": "vigafyde indicated monotherapy treatment nfantile spasms pediatric patients 1 month 2 years age potential benefits outweigh potential risk vision loss ( 1 )",
        "doid_entities": [
            {
                "text": "vision loss (DOID:1432)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1432"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "vigafyde concentrated formulation compared vigabatrin products . verify strength dose product prior prescribing , dispensing , administering ( 2.1 ) initiate daily 50 mg/kg ( 25 mg/kg twice daily ) ; increase total daily every 3 days , increments 25 mg/kg/day 50 mg/kg/day , maximum daily 150 mg/kg ( 75 mg/kg twice daily ) ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "vigafyde ( vigabatrin ) oral solution contains 100 mg/ml vigabatrin . clear , colorless light yellow , peppermint-flavored solution supplied white opaque high-density polyethylene ( hdpe ) 150 ml bottle carton ( ndc 80789-003-15 ) .",
    "adverseReactions": "none .",
    "indications_original": "VIGAFYDE\u00a0is indicated as monotherapy for the treatment of i nfantile spasms in pediatric patients 1\u00a0month to 2\u00a0years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1 )",
    "contraindications_original": "VIGAFYDE is a concentrated formulation as compared to other vigabatrin products. Verify the strength and the dose of the product prior to prescribing, dispensing, and administering ( 2.1 ) Initiate at a daily dosage of 50 mg/kg (25 mg/kg twice daily); increase total daily dosage every 3 days, in increments of 25 mg/kg/day to 50 mg/kg/day, up to a maximum daily dosage of 150 mg/kg (75 mg/kg twice daily) ( 2.2 )",
    "warningsAndPrecautions_original": "VIGAFYDE (vigabatrin) oral solution contains 100 mg/mL vigabatrin. It is a clear, colorless to light yellow, peppermint-flavored solution supplied in a white opaque high-density polyethylene (HDPE) 150 mL bottle in a carton (NDC 80789-003-15).",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "VIGAFYDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63638"
        }
    ]
}